Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

Background: Neoadjuvant chemotherapy (NAC) has been of recent interest as an alternative to upfront surgery followed by adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). However, a subset of patients does not respond to NAC and may have been better managed by upfront su...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahni, Sumit, Nahm, Christopher, Krisp, Christoph, Molloy, Mark P., Mehta, Shreya, Maloney, Sarah, Itchins, Malinda, Pavlakis, Nick, Clarke, Stephen, Chan, David, Gill, Anthony J., Howell, Viive M., Samra, Jaswinder, Mittal, Anubhav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064619/
https://www.ncbi.nlm.nih.gov/pubmed/32195182
http://dx.doi.org/10.3389/fonc.2020.00237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064619/
https://www.ncbi.nlm.nih.gov/pubmed/32195182
http://dx.doi.org/10.3389/fonc.2020.00237

Ejemplares similares